[HTML][HTML] SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the …
L Ma, R Zou, W Shi, N Zhou, S Chen, H Zhou… - Theranostics, 2022 - ncbi.nlm.nih.gov
Background: Given the importance of microvascular injury in infarct formation and
expansion, development of therapeutic strategies for microvascular protection against …
expansion, development of therapeutic strategies for microvascular protection against …
SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO …
L Ma, R Zou, W Shi, N Zhou, S Chen, H Zhou… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background: Given the importance of microvascular injury in infarct formation and
expansion, development of therapeutic strategies for microvascular protection against …
expansion, development of therapeutic strategies for microvascular protection against …
SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO …
M Li, R Zou, W Shi, N Zhou, S Chen, H Zhou… - …, 2022 - search.proquest.com
Background: Given the importance of microvascular injury in infarct formation and
expansion, development of therapeutic strategies for microvascular protection against …
expansion, development of therapeutic strategies for microvascular protection against …
SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO …
L Ma, R Zou, W Shi, N Zhou, S Chen, H Zhou… - Theranostics, 2022 - europepmc.org
Background: Given the importance of microvascular injury in infarct formation and
expansion, development of therapeutic strategies for microvascular protection against …
expansion, development of therapeutic strategies for microvascular protection against …